Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on RVNC. Barclays decreased their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Finally, Mizuho dropped their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Thursday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $6.65. The stock has a 50-day moving average price of $3.65 and a 200-day moving average price of $4.05. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RVNC. CIBRA Capital Ltd bought a new stake in shares of Revance Therapeutics in the fourth quarter worth about $3,466,000. Alpine Global Management LLC bought a new stake in Revance Therapeutics in the 4th quarter worth approximately $37,000. Two Sigma Investments LP raised its holdings in shares of Revance Therapeutics by 8.6% during the 4th quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock worth $517,000 after acquiring an additional 13,539 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Revance Therapeutics by 19.3% during the 4th quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,155 shares during the last quarter. Finally, Man Group plc grew its holdings in shares of Revance Therapeutics by 47.8% in the fourth quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after purchasing an additional 143,544 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.